TY - JOUR
AU1 - KUMAOKA,, SOICHI
AU2 - TAKATANI,, OSAMU
AU3 - YOSHIDA,, MINORU
AU4 - MIURA,, SHIGETO
AU5 - TAKAO,, TETSUTO
AU6 - HAMANAKA,, YÜJI
AU7 - IZUO,, MASARU
AU8 - OKADA,, TADAKAZU
AB - Abstract A new orally active anti-estrogenic steroid, 2α,3α-epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether (10364-S) was given to 41 advanced breast cancer patients. Most patients were given a daily dose of 20 mg. The study was preliminary and not a controlled trial using an already proven androgenic steroid. The remission rate on giving this compound to advanced breast cancer was 11/41 or 26.8% and the average duration of the remission was 10.5 months. Hoarseness (8/41, 19.5%) and hirsutism (5/41, 12.2%) were relatively often seen as virilizing side effects. No unfavorable effects on the hematopoietic organs, the liver or on calcium metabolism were recognized in the study. This content is only available as a PDF. © 1974 JAPANESE JOURNAL OF CLINICAL ONCOLOGY
TI - 2α,3α-Epithio-5α-androstan-17β-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial—
JF - Japanese Journal of Clinical Oncology
DO - 10.1093/oxfordjournals.jjco.a039837
DA - 1974-06-01
UR - https://www.deepdyve.com/lp/oxford-university-press/2-3-epithio-5-androstan-17-yl-1-methoxycyclopentyl-ether-in-the-ihDLdf0GwR
SP - 65
EP - 68
VL - 4
IS - 1
DP - DeepDyve
ER -